autologous bone marrow-derived mononuclear cells
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02914171 | Sep 2016 → Mar 2021 | Ebstein anomaly | Timothy J. Nelson | Completed | No outcome recorded |
| Phase 1 | NCT02549625 | Aug 2015 → Nov 2020 | congenital heart disease | Timothy J Nelson, MD, PhD | Completed | No outcome recorded |
| Phase 1 | NCT00874354 | Jul 2005 → Jun 2013 | myocardial infarction | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03145402 | Oct 2020 → Aug 2021 | heart failure | SCARM Institute, Tabriz, Iran | Unknown | No outcome recorded |
| Phase 1/2 | NCT03227198 | Oct 2020 → Aug 2021 | heart failure | SCARM Institute, Tabriz, Iran | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05711849 | Mar 2024 → Aug 2026 overdue | — | Barts & The London NHS Trust | Recruiting | No outcome recorded |
| Phase 2 | NCT04528550 | Oct 2020 → Oct 2023 | spinal cord injury | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02923817 | Sep 2016 → Dec 2018 | spinal cord injury | Da Nang Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01984814 | Dec 2008 → Aug 2013 | amyotrophic lateral sclerosis | Neurogen Brain and Spine Institute | Withdrawn | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT01759823 | Dec 2012 → Dec 2014 | type 2 diabetes mellitus | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT01693042 Comparator | Nov 2013 → Nov 2022 | heart failure | Johann Wolfgang Goethe University Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous bone marrow derived-mononuclear cells | “Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.” NCT00874354 ↗11“Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest.” NCT03145402 ↗ “Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest.” NCT03227198 ↗ “Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.” NCT01984814 ↗ “Patients will be randomized to either autologous bone marrow derived-mononuclear cells or a sham procedure.” PMID 38862073 ↗ Jun 2024 “autologous bone marrow-derived mononuclear cells (ABM-MNCs) transplantation” PMID 28690682 ↗ Jul 2017 “autologous bone marrow-derived mononuclear cells” NCT01693042 ↗ |
| Known as | ABM-MNCs | “autologous bone marrow-derived mononuclear cells (ABM-MNCs) transplantation” PMID 28690682 ↗ Jul 2017 |
| Known as | autologous bone marrow-derived unfractionated mononuclear cells | “CONCLUSIONS: This is the first trial to assess the safety and efficacy of an intracoronary infusion of autologous bone marrow-derived unfractionated mononuclear cells in...” PMID 38862073 ↗ Jun 2024 |
| Known as | MNS | “autologous mononuclear cells (MNS) collected from bone marrow (BM)” NCT02914171 ↗ |
| Modality | Cell therapy | “stem cell therapy” NCT00874354 ↗ |
| Route | Other | “Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.” NCT00874354 ↗ |